Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

IGC Pharma (IGC) Depreciation & Amortization (IS) (2016 - 2017)

IGC Pharma (IGC) has disclosed Depreciation & Amortization (IS) for 5 consecutive years, with $4989.0 as the latest value for Q4 2017.

  • On a quarterly basis, Depreciation & Amortization (IS) fell 97.45% to $4989.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$180806.0, a 126.89% decrease, with the full-year FY2017 number at $195514.0, down 73.17% from a year prior.
  • Depreciation & Amortization (IS) was $4989.0 for Q4 2017 at IGC Pharma, up from $4344.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $323778.0 in Q1 2015 to a low of -$196103.0 in Q1 2017.
  • A 5-year average of $118624.0 and a median of $147850.0 in 2013 define the central range for Depreciation & Amortization (IS).
  • Peak YoY movement for Depreciation & Amortization (IS): surged 37.06% in 2016, then crashed 169.8% in 2017.
  • IGC Pharma's Depreciation & Amortization (IS) stood at $147708.0 in 2013, then rose by 4.07% to $153725.0 in 2014, then dropped by 6.98% to $143000.0 in 2015, then soared by 37.06% to $196000.0 in 2016, then plummeted by 97.45% to $4989.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Depreciation & Amortization (IS) are $4989.0 (Q4 2017), $4344.0 (Q3 2017), and $5964.0 (Q2 2017).